Q3-osavuosiraportti
8 päivää sitten‧41 min
Tarjoustasot
Euronext Paris
Määrä
Osto
490
Myynti
Määrä
144
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
4,42VWAP
Alin
3,912VaihtoMäärä
7 1 699 821
VWAP
Ylin
4,42Alin
3,912VaihtoMäärä
7 1 699 821
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3-osavuosiraportti | 20.11. | |
| 2025 Q2-osavuosiraportti | 12.8. | |
| 2025 Yhtiökokous | 25.6. | |
| 2025 Q1-osavuosiraportti | 7.5. | |
| 2024 Vuosiraportti | 24.3. |
Datan lähde: Morningstar, Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·22.11.For those who prefer to read directly from the source of my latest posts, I have posted the link to Valneva's raoort a bit further down in the feed. In addition, you will find most of it here (in German): https://live.deutsche-boerse.com/nachrichten/GNW-News-Valneva-gibt-Finanzergebnisse-fuer-die-ersten-neun-Monate-2025-bekannt-und-informiert-ueber-Unternehmensentwicklungen-40279ee5-a1ef-40d8-b265-d125c55d7258- ·22.11.From the Q3 report Vaccine candidates in clinical development Lyme disease vaccine candidate – VLA15 Phase 3 VALOR study on track Valneva and Pfizer are developing VLA15, a vaccine candidate against the Borrelia bacterium, which causes Lyme disease. Pfizer is currently conducting the randomized, placebo-controlled Phase 3 study VALOR (Vaccine Against Lyme for Outdoor Recreationists). Vaccinations are complete, and Valneva expects results from the study in the first half of 2026. These will form the basis for planned marketing authorization applications. If the data are positive, Pfizer will submit a Biologics License Application (BLA) to the FDA in the USA and a Marketing Authorization Application (MAA) to the EMA in Europe. Shigella vaccine candidate – S4V2 Two Phase 2 studies ongoing S4V2 is the world's most advanced tetravalent vaccine candidate against shigellosis, the second most common cause of fatal diarrhea globally. Two clinical studies are ongoing: A Phase 2 study assessing safety and immune response in infants. A Phase 2b Human Challenge Study (CHIM), sponsored by LimmaTech Biologics AG. If the results are positive, Valneva will take over further development. As of today, there is no approved multivalent Shigella vaccine, and WHO has classified the development of such vaccines as a global priority. In October 2024, the FDA granted S4V2 fast-track status, recognizing its potential to address a significant medical need. The global market for a Shigella vaccine is estimated at over 500 million dollars annually. Zika vaccine candidate – VLA1601 Positive Phase 1 results Valneva has recently achieved promising results from the Phase 1 study of VLA1601, an inactivated vaccine candidate against the Zika virus. Data up to day 57 (four weeks after the second dose) showed that the vaccine was safe, well-tolerated, and immunogenic in all five treatment groups. Despite the medical need, both regulatory pathways and market opportunities for Zika vaccines are uncertain. Valneva will therefore only consider further development if concrete funding opportunities – private or public – become available.
- ·22.11.From the Q3 report Strategic agreements In June 2025, Valneva entered into an exclusive agreement with CSL Seqirus, the world's largest manufacturer of influenza vaccines, for the marketing and distribution of three of Valneva's own vaccines in Germany. From January 2026, IXCHIQ® (the chikungunya vaccine) will be available. In addition, IXIARO® (Japanese encephalitis) and DUKORAL® (cholera/ETEC) will be distributed through CSL Seqirus. Sales development per vaccine IXIARO®/JESPECT®: Sales increased by 12.5 % to 74.3 million euro (from 66.0 million euro in 2024). Growth came particularly from travelers and the US military. Currency fluctuations had a negative effect of 0.8 million euro. DUKORAL®: Sales were 21.5 million euro, down from 22.3 million euro in 2024. The decline was mainly due to a weak Canadian dollar and lower revenues in Germany. IXCHIQ®: Revenue rose to 7.6 million euro (from 1.8 million euro in 2024), driven by deliveries to combat the chikungunya outbreak on La Réunion. Temporary restrictions from the FDA have affected revenues in the travel segment, but Valneva is awaiting further clarifications from US authorities. Clinical data Valneva recently presented positive long-term data showing that a single dose of IXCHIQ® provides 95 % seroresponse four years after vaccination. The effect is comparable in both older (65+) and younger adults, which supports the vaccine as an important tool for both travelers and populations in endemic areas.
- ·22.11. · MuokattuFrom the Q3 report Financial report – first nine months 2025 (unaudited, consolidated according to IFRS) Revenue Total revenues: 127.0 million euro (up from 116.6 million in 2024). Total sales: 119.4 million euro (up from 112.5 million in 2024). The growth of 6.2% was driven by IXIARO®/JESPECT® and IXCHIQ®, while discontinuation of third-party products and foreign exchange fluctuations of -1.3 million euro had a negative effect. Other revenues (collaborations, licenses, services): 7.6 million euro, up from 4.2 million in 2024, mainly from the license agreement with Serum Institute of India for the chikungunya vaccine. Operating profit and EBITDA Cost of goods and services sold (COGS): 71.1 million euro (compared to 71.3 million in 2024). Gross margin (excl. IXCHIQ®): 57.2%, up from 48.6% in 2024, driven by better production performance and favorable product mix. Research and development costs: 59.7 million euro (up from 48.6 million), mainly related to the Shigella program and Phase 4 commitments for IXCHIQ®. Marketing and sales expenses: 28.6 million euro, down from 35.7 million in 2024, due to lower advertising and consulting costs. Administrative expenses: 29.5 million euro, down from 32.6 million in 2024. Operating profit: -53.9 million euro, compared to +34.2 million in 2024 (the difference is due to the sale of PRV in 2024). Adjusted EBITDA: -37.7 million euro, compared to +48.6 million in 2024. Net result Net loss: 65.2 million euro, compared to a net profit of 24.7 million in 2024 (driven by the PRV sale). Net financial costs: 9.1 million euro, down from 13.4 million in 2024, affected by USD/EUR exchange rate development. Cash flow and liquidity Cash flow from operations: 28.4 million euro, down from 76.7 million in 2024. Cash flow from investments: -1.4 million euro, compared to +72.2 million in 2024 (due to the PRV sale). Cash flow from financing: +8.7 million euro, compared to +35.3 million in 2024. Cash and equivalents as of September 30, 2025: 143.5 million euro, down from 168.3 million as of December 31, 2024. Non-IFRS financial key figures Management reports both IFRS results and non-IFRS measures as a supplement to assess and communicate the company's performance. Although non-IFRS measures should not be considered an alternative to IFRS results, management believes that these measurements provide useful insights into ongoing performance and contribute to a better understanding of Valneva's development and financial situation. Adjusted EBITDA is a commonly used supplementary measure among investors and financial analysts. Management considers this a valuable tool for further analysis. Adjusted EBITDA is defined as net profit (or loss) for the period before income tax, financial income and costs, foreign exchange gains/losses, depreciation and amortization. For the first nine months of 2025, Valneva had a net loss of 65.2 million euro, compared to a net profit of 24.7 million euro in the same period 2024. When adding income tax of 2.1 million euro (compared to -3.9 million in 2024), subtracting financial income of -1.9 million euro (compared to -1.3 million in 2024), and including financial costs of 17.3 million euro (compared to 17.7 million in 2024), one gets a more comprehensive picture. Furthermore, foreign exchange gains of -6.3 million euro (compared to -3.0 million in 2024), amortization of 3.6 million euro (compared to 3.7 million in 2024), as well as depreciation of 12.6 million euro (compared to 10.7 million in 2024). Overall, this results in an adjusted EBITDA of -37.7 million euro in 2025, compared to +48.6 million euro in 2024.
- ·22.11.From the Q3 report Valneva's portfolio consists of three travel vaccines: IXIARO®/JESPECT® DUKORAL® IXCHIQ® (recently introduced) In addition, the company distributes certain third-party products in markets where it has its own sales and marketing infrastructure. Financial results Revenues for the first nine months of 2025 amounted to 119.4 million euro, up from 112.5 million euro in the same period of 2024. Sales of third-party products fell to 16.1 million euro (from 22.5 million euro in 2024), due to the discontinuation of the distribution of Rabipur®/RabAvert® and Encepur® in the UK and Canada from January 2025. The share of third-party sales will gradually decrease to below 5 % of total revenue by 2026/2027, which may improve the company's gross margins.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Q3-osavuosiraportti
8 päivää sitten‧41 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·22.11.For those who prefer to read directly from the source of my latest posts, I have posted the link to Valneva's raoort a bit further down in the feed. In addition, you will find most of it here (in German): https://live.deutsche-boerse.com/nachrichten/GNW-News-Valneva-gibt-Finanzergebnisse-fuer-die-ersten-neun-Monate-2025-bekannt-und-informiert-ueber-Unternehmensentwicklungen-40279ee5-a1ef-40d8-b265-d125c55d7258
- ·22.11.From the Q3 report Vaccine candidates in clinical development Lyme disease vaccine candidate – VLA15 Phase 3 VALOR study on track Valneva and Pfizer are developing VLA15, a vaccine candidate against the Borrelia bacterium, which causes Lyme disease. Pfizer is currently conducting the randomized, placebo-controlled Phase 3 study VALOR (Vaccine Against Lyme for Outdoor Recreationists). Vaccinations are complete, and Valneva expects results from the study in the first half of 2026. These will form the basis for planned marketing authorization applications. If the data are positive, Pfizer will submit a Biologics License Application (BLA) to the FDA in the USA and a Marketing Authorization Application (MAA) to the EMA in Europe. Shigella vaccine candidate – S4V2 Two Phase 2 studies ongoing S4V2 is the world's most advanced tetravalent vaccine candidate against shigellosis, the second most common cause of fatal diarrhea globally. Two clinical studies are ongoing: A Phase 2 study assessing safety and immune response in infants. A Phase 2b Human Challenge Study (CHIM), sponsored by LimmaTech Biologics AG. If the results are positive, Valneva will take over further development. As of today, there is no approved multivalent Shigella vaccine, and WHO has classified the development of such vaccines as a global priority. In October 2024, the FDA granted S4V2 fast-track status, recognizing its potential to address a significant medical need. The global market for a Shigella vaccine is estimated at over 500 million dollars annually. Zika vaccine candidate – VLA1601 Positive Phase 1 results Valneva has recently achieved promising results from the Phase 1 study of VLA1601, an inactivated vaccine candidate against the Zika virus. Data up to day 57 (four weeks after the second dose) showed that the vaccine was safe, well-tolerated, and immunogenic in all five treatment groups. Despite the medical need, both regulatory pathways and market opportunities for Zika vaccines are uncertain. Valneva will therefore only consider further development if concrete funding opportunities – private or public – become available.
- ·22.11.From the Q3 report Strategic agreements In June 2025, Valneva entered into an exclusive agreement with CSL Seqirus, the world's largest manufacturer of influenza vaccines, for the marketing and distribution of three of Valneva's own vaccines in Germany. From January 2026, IXCHIQ® (the chikungunya vaccine) will be available. In addition, IXIARO® (Japanese encephalitis) and DUKORAL® (cholera/ETEC) will be distributed through CSL Seqirus. Sales development per vaccine IXIARO®/JESPECT®: Sales increased by 12.5 % to 74.3 million euro (from 66.0 million euro in 2024). Growth came particularly from travelers and the US military. Currency fluctuations had a negative effect of 0.8 million euro. DUKORAL®: Sales were 21.5 million euro, down from 22.3 million euro in 2024. The decline was mainly due to a weak Canadian dollar and lower revenues in Germany. IXCHIQ®: Revenue rose to 7.6 million euro (from 1.8 million euro in 2024), driven by deliveries to combat the chikungunya outbreak on La Réunion. Temporary restrictions from the FDA have affected revenues in the travel segment, but Valneva is awaiting further clarifications from US authorities. Clinical data Valneva recently presented positive long-term data showing that a single dose of IXCHIQ® provides 95 % seroresponse four years after vaccination. The effect is comparable in both older (65+) and younger adults, which supports the vaccine as an important tool for both travelers and populations in endemic areas.
- ·22.11. · MuokattuFrom the Q3 report Financial report – first nine months 2025 (unaudited, consolidated according to IFRS) Revenue Total revenues: 127.0 million euro (up from 116.6 million in 2024). Total sales: 119.4 million euro (up from 112.5 million in 2024). The growth of 6.2% was driven by IXIARO®/JESPECT® and IXCHIQ®, while discontinuation of third-party products and foreign exchange fluctuations of -1.3 million euro had a negative effect. Other revenues (collaborations, licenses, services): 7.6 million euro, up from 4.2 million in 2024, mainly from the license agreement with Serum Institute of India for the chikungunya vaccine. Operating profit and EBITDA Cost of goods and services sold (COGS): 71.1 million euro (compared to 71.3 million in 2024). Gross margin (excl. IXCHIQ®): 57.2%, up from 48.6% in 2024, driven by better production performance and favorable product mix. Research and development costs: 59.7 million euro (up from 48.6 million), mainly related to the Shigella program and Phase 4 commitments for IXCHIQ®. Marketing and sales expenses: 28.6 million euro, down from 35.7 million in 2024, due to lower advertising and consulting costs. Administrative expenses: 29.5 million euro, down from 32.6 million in 2024. Operating profit: -53.9 million euro, compared to +34.2 million in 2024 (the difference is due to the sale of PRV in 2024). Adjusted EBITDA: -37.7 million euro, compared to +48.6 million in 2024. Net result Net loss: 65.2 million euro, compared to a net profit of 24.7 million in 2024 (driven by the PRV sale). Net financial costs: 9.1 million euro, down from 13.4 million in 2024, affected by USD/EUR exchange rate development. Cash flow and liquidity Cash flow from operations: 28.4 million euro, down from 76.7 million in 2024. Cash flow from investments: -1.4 million euro, compared to +72.2 million in 2024 (due to the PRV sale). Cash flow from financing: +8.7 million euro, compared to +35.3 million in 2024. Cash and equivalents as of September 30, 2025: 143.5 million euro, down from 168.3 million as of December 31, 2024. Non-IFRS financial key figures Management reports both IFRS results and non-IFRS measures as a supplement to assess and communicate the company's performance. Although non-IFRS measures should not be considered an alternative to IFRS results, management believes that these measurements provide useful insights into ongoing performance and contribute to a better understanding of Valneva's development and financial situation. Adjusted EBITDA is a commonly used supplementary measure among investors and financial analysts. Management considers this a valuable tool for further analysis. Adjusted EBITDA is defined as net profit (or loss) for the period before income tax, financial income and costs, foreign exchange gains/losses, depreciation and amortization. For the first nine months of 2025, Valneva had a net loss of 65.2 million euro, compared to a net profit of 24.7 million euro in the same period 2024. When adding income tax of 2.1 million euro (compared to -3.9 million in 2024), subtracting financial income of -1.9 million euro (compared to -1.3 million in 2024), and including financial costs of 17.3 million euro (compared to 17.7 million in 2024), one gets a more comprehensive picture. Furthermore, foreign exchange gains of -6.3 million euro (compared to -3.0 million in 2024), amortization of 3.6 million euro (compared to 3.7 million in 2024), as well as depreciation of 12.6 million euro (compared to 10.7 million in 2024). Overall, this results in an adjusted EBITDA of -37.7 million euro in 2025, compared to +48.6 million euro in 2024.
- ·22.11.From the Q3 report Valneva's portfolio consists of three travel vaccines: IXIARO®/JESPECT® DUKORAL® IXCHIQ® (recently introduced) In addition, the company distributes certain third-party products in markets where it has its own sales and marketing infrastructure. Financial results Revenues for the first nine months of 2025 amounted to 119.4 million euro, up from 112.5 million euro in the same period of 2024. Sales of third-party products fell to 16.1 million euro (from 22.5 million euro in 2024), due to the discontinuation of the distribution of Rabipur®/RabAvert® and Encepur® in the UK and Canada from January 2025. The share of third-party sales will gradually decrease to below 5 % of total revenue by 2026/2027, which may improve the company's gross margins.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Euronext Paris
Määrä
Osto
490
Myynti
Määrä
144
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
4,42VWAP
Alin
3,912VaihtoMäärä
7 1 699 821
VWAP
Ylin
4,42Alin
3,912VaihtoMäärä
7 1 699 821
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3-osavuosiraportti | 20.11. | |
| 2025 Q2-osavuosiraportti | 12.8. | |
| 2025 Yhtiökokous | 25.6. | |
| 2025 Q1-osavuosiraportti | 7.5. | |
| 2024 Vuosiraportti | 24.3. |
Datan lähde: Morningstar, Quartr
Q3-osavuosiraportti
8 päivää sitten‧41 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3-osavuosiraportti | 20.11. | |
| 2025 Q2-osavuosiraportti | 12.8. | |
| 2025 Yhtiökokous | 25.6. | |
| 2025 Q1-osavuosiraportti | 7.5. | |
| 2024 Vuosiraportti | 24.3. |
Datan lähde: Morningstar, Quartr
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·22.11.For those who prefer to read directly from the source of my latest posts, I have posted the link to Valneva's raoort a bit further down in the feed. In addition, you will find most of it here (in German): https://live.deutsche-boerse.com/nachrichten/GNW-News-Valneva-gibt-Finanzergebnisse-fuer-die-ersten-neun-Monate-2025-bekannt-und-informiert-ueber-Unternehmensentwicklungen-40279ee5-a1ef-40d8-b265-d125c55d7258
- ·22.11.From the Q3 report Vaccine candidates in clinical development Lyme disease vaccine candidate – VLA15 Phase 3 VALOR study on track Valneva and Pfizer are developing VLA15, a vaccine candidate against the Borrelia bacterium, which causes Lyme disease. Pfizer is currently conducting the randomized, placebo-controlled Phase 3 study VALOR (Vaccine Against Lyme for Outdoor Recreationists). Vaccinations are complete, and Valneva expects results from the study in the first half of 2026. These will form the basis for planned marketing authorization applications. If the data are positive, Pfizer will submit a Biologics License Application (BLA) to the FDA in the USA and a Marketing Authorization Application (MAA) to the EMA in Europe. Shigella vaccine candidate – S4V2 Two Phase 2 studies ongoing S4V2 is the world's most advanced tetravalent vaccine candidate against shigellosis, the second most common cause of fatal diarrhea globally. Two clinical studies are ongoing: A Phase 2 study assessing safety and immune response in infants. A Phase 2b Human Challenge Study (CHIM), sponsored by LimmaTech Biologics AG. If the results are positive, Valneva will take over further development. As of today, there is no approved multivalent Shigella vaccine, and WHO has classified the development of such vaccines as a global priority. In October 2024, the FDA granted S4V2 fast-track status, recognizing its potential to address a significant medical need. The global market for a Shigella vaccine is estimated at over 500 million dollars annually. Zika vaccine candidate – VLA1601 Positive Phase 1 results Valneva has recently achieved promising results from the Phase 1 study of VLA1601, an inactivated vaccine candidate against the Zika virus. Data up to day 57 (four weeks after the second dose) showed that the vaccine was safe, well-tolerated, and immunogenic in all five treatment groups. Despite the medical need, both regulatory pathways and market opportunities for Zika vaccines are uncertain. Valneva will therefore only consider further development if concrete funding opportunities – private or public – become available.
- ·22.11.From the Q3 report Strategic agreements In June 2025, Valneva entered into an exclusive agreement with CSL Seqirus, the world's largest manufacturer of influenza vaccines, for the marketing and distribution of three of Valneva's own vaccines in Germany. From January 2026, IXCHIQ® (the chikungunya vaccine) will be available. In addition, IXIARO® (Japanese encephalitis) and DUKORAL® (cholera/ETEC) will be distributed through CSL Seqirus. Sales development per vaccine IXIARO®/JESPECT®: Sales increased by 12.5 % to 74.3 million euro (from 66.0 million euro in 2024). Growth came particularly from travelers and the US military. Currency fluctuations had a negative effect of 0.8 million euro. DUKORAL®: Sales were 21.5 million euro, down from 22.3 million euro in 2024. The decline was mainly due to a weak Canadian dollar and lower revenues in Germany. IXCHIQ®: Revenue rose to 7.6 million euro (from 1.8 million euro in 2024), driven by deliveries to combat the chikungunya outbreak on La Réunion. Temporary restrictions from the FDA have affected revenues in the travel segment, but Valneva is awaiting further clarifications from US authorities. Clinical data Valneva recently presented positive long-term data showing that a single dose of IXCHIQ® provides 95 % seroresponse four years after vaccination. The effect is comparable in both older (65+) and younger adults, which supports the vaccine as an important tool for both travelers and populations in endemic areas.
- ·22.11. · MuokattuFrom the Q3 report Financial report – first nine months 2025 (unaudited, consolidated according to IFRS) Revenue Total revenues: 127.0 million euro (up from 116.6 million in 2024). Total sales: 119.4 million euro (up from 112.5 million in 2024). The growth of 6.2% was driven by IXIARO®/JESPECT® and IXCHIQ®, while discontinuation of third-party products and foreign exchange fluctuations of -1.3 million euro had a negative effect. Other revenues (collaborations, licenses, services): 7.6 million euro, up from 4.2 million in 2024, mainly from the license agreement with Serum Institute of India for the chikungunya vaccine. Operating profit and EBITDA Cost of goods and services sold (COGS): 71.1 million euro (compared to 71.3 million in 2024). Gross margin (excl. IXCHIQ®): 57.2%, up from 48.6% in 2024, driven by better production performance and favorable product mix. Research and development costs: 59.7 million euro (up from 48.6 million), mainly related to the Shigella program and Phase 4 commitments for IXCHIQ®. Marketing and sales expenses: 28.6 million euro, down from 35.7 million in 2024, due to lower advertising and consulting costs. Administrative expenses: 29.5 million euro, down from 32.6 million in 2024. Operating profit: -53.9 million euro, compared to +34.2 million in 2024 (the difference is due to the sale of PRV in 2024). Adjusted EBITDA: -37.7 million euro, compared to +48.6 million in 2024. Net result Net loss: 65.2 million euro, compared to a net profit of 24.7 million in 2024 (driven by the PRV sale). Net financial costs: 9.1 million euro, down from 13.4 million in 2024, affected by USD/EUR exchange rate development. Cash flow and liquidity Cash flow from operations: 28.4 million euro, down from 76.7 million in 2024. Cash flow from investments: -1.4 million euro, compared to +72.2 million in 2024 (due to the PRV sale). Cash flow from financing: +8.7 million euro, compared to +35.3 million in 2024. Cash and equivalents as of September 30, 2025: 143.5 million euro, down from 168.3 million as of December 31, 2024. Non-IFRS financial key figures Management reports both IFRS results and non-IFRS measures as a supplement to assess and communicate the company's performance. Although non-IFRS measures should not be considered an alternative to IFRS results, management believes that these measurements provide useful insights into ongoing performance and contribute to a better understanding of Valneva's development and financial situation. Adjusted EBITDA is a commonly used supplementary measure among investors and financial analysts. Management considers this a valuable tool for further analysis. Adjusted EBITDA is defined as net profit (or loss) for the period before income tax, financial income and costs, foreign exchange gains/losses, depreciation and amortization. For the first nine months of 2025, Valneva had a net loss of 65.2 million euro, compared to a net profit of 24.7 million euro in the same period 2024. When adding income tax of 2.1 million euro (compared to -3.9 million in 2024), subtracting financial income of -1.9 million euro (compared to -1.3 million in 2024), and including financial costs of 17.3 million euro (compared to 17.7 million in 2024), one gets a more comprehensive picture. Furthermore, foreign exchange gains of -6.3 million euro (compared to -3.0 million in 2024), amortization of 3.6 million euro (compared to 3.7 million in 2024), as well as depreciation of 12.6 million euro (compared to 10.7 million in 2024). Overall, this results in an adjusted EBITDA of -37.7 million euro in 2025, compared to +48.6 million euro in 2024.
- ·22.11.From the Q3 report Valneva's portfolio consists of three travel vaccines: IXIARO®/JESPECT® DUKORAL® IXCHIQ® (recently introduced) In addition, the company distributes certain third-party products in markets where it has its own sales and marketing infrastructure. Financial results Revenues for the first nine months of 2025 amounted to 119.4 million euro, up from 112.5 million euro in the same period of 2024. Sales of third-party products fell to 16.1 million euro (from 22.5 million euro in 2024), due to the discontinuation of the distribution of Rabipur®/RabAvert® and Encepur® in the UK and Canada from January 2025. The share of third-party sales will gradually decrease to below 5 % of total revenue by 2026/2027, which may improve the company's gross margins.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Euronext Paris
Määrä
Osto
490
Myynti
Määrä
144
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
4,42VWAP
Alin
3,912VaihtoMäärä
7 1 699 821
VWAP
Ylin
4,42Alin
3,912VaihtoMäärä
7 1 699 821
Välittäjätilasto
Dataa ei löytynyt